Epratuzumab
Epratuzumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target B-cell receptor CD22.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
41 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | C85.9 | 4 | 4 | — | — | 1 | 6 | |
| Leukemia | D007938 | C95 | 3 | 4 | — | — | — | 5 | |
| B-cell lymphoma | D016393 | 1 | 2 | — | — | — | 2 | ||
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | 1 | 1 | — | — | — | 1 | ||
| Follicular lymphoma | D008224 | C82 | 1 | 1 | — | — | — | 1 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 1 | 1 | — | — | — | 1 | |
| Waldenstrom macroglobulinemia | D008258 | C88.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | EPRATUZUMAB |
| INN | epratuzumab |
| Description | Epratuzumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >5VKK:H,A|Epratuzumab Fab Heavy Chain
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIGYINPRNDYTEYNQNFKDKATITADESTNTAY
MELSSLRSEDTAFYFCARRDITTFYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG
ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
>5VKK:L,B|Epratuzumab Fab Light Chain
DIQLTQSPSSLSASVGDRVTMSCKSSQSVLYSANHKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLT
ISSLQPEDIATYYCHQYLSSWTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ
SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
| PDB | 5VKK, 5VL3 |
| CAS-ID | 205923-57-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108404 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB04958 |
| UNII ID | 3062P60MH9 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CD22
CD22
Organism
Homo sapiens
Gene name
CD22
Gene synonyms
SIGLEC2
NCBI Gene ID
Protein name
B-cell receptor CD22
Protein synonyms
B-lymphocyte cell adhesion molecule, BL-CAM, CD22, CD22 antigen, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14
Uniprot ID
Mouse ortholog
Cd22 (12483)
B-cell receptor CD22 (Q9WU51)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 954 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
32 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more